Utilize prostate specific antigen (PSA) and other biomarkers to minimize unnecessary testing and biopsy when screening men who are at average risk for prostate cancer.
Classify the principles of “risk-adapted” screening for men at elevated risk for prostate cancer based on race, family history, early in life PSA, polygenic risk scores and specific genetic mutations (e.g., BRCA1/2).
Explain the roles of magnetic resonance imaging (MRI), high frequency ultrasound and transperineal approaches to improve prostate biopsy.
Explain the use of positron emission tomography (PET) imaging to better stage men with high-risk disease, to better characterize men with biochemical recurrence and to guide metastasis-directed therapy in men with oligometastatic disease.
Describe how to choose and sequence secondary and tertiary hormonal, chemotherapeutic, immunological and/or targeted therapies (e.g., PARP inhibitors) in men with metastatic and castrate resistant prostate cancer.
This course will provide a practical update on each of the following areas of prostate cancer: Screening and early detection, new biomarkers, new Imaging and Biopsy techniques, new agents to manage advanced/metastatic prostate cancer